TL;DR
A study published online Aug. 17 in the Chinese Medical Journal developed age-specific AMH reference values for Chinese women aged 35–55 using an ultrasensitive assay. The researchers reported links between lower AMH and diminished ovarian reserve risk and perimenopausal symptoms, but AMH alone had only moderate ability to distinguish menopausal status.
A research team in China has developed age-specific reference values for anti-Müllerian hormone (AMH) in women aged 35–55, using an ultrasensitive assay to measure low hormone levels during the years around the menopausal transition. The study, published online Aug. 17 in the Chinese Medical Journal, links lower AMH levels with a greater risk of severely diminished ovarian reserve and more severe perimenopausal symptoms, while finding that AMH alone is not a reliable stand-alone menopause test.
Led by Professor Yingying Qin of Shandong University and Professor Ruimin Zheng of China’s National Center for Women and Children’s Health, the researchers built a reference table from a large nationwide cohort of Chinese women. It is designed to let clinicians compare a woman’s AMH result with values for people of the same age, rather than relying mainly on ranges drawn from younger, reproductive-age populations. The study is by Xu and colleagues and is titled “Age-specific anti-Müllerian hormone reference values using an ultrasensitive assay: Associations with ovarian aging and menopausal transition symptoms.”
The researchers also examined the framework in a hospital-based care cohort. Among women aged 35–40 who still planned to conceive, participants whose starting AMH was below the 10th percentile for their age had a higher risk of progressing to severely diminished ovarian reserve, defined in the report as AMH below 0.25 ng/mL, than women in the usual percentile range. The source describes this as a potential aid to fertility counseling and planning; it does not report that the test predicts an individual’s ability to conceive.
In women aged 35–55, lower AMH was also associated with a greater likelihood of more severe perimenopausal symptoms, especially hot flashes and sweating. For menopausal status, the study reported average AMH levels of 0.187 ng/mL in premenopausal women and 0.043 ng/mL in postmenopausal women. AMH’s ability to distinguish the two groups was moderate, with an area under the curve of about 0.7. The authors’ account says very low results may support clinical assessment, particularly when other hormone levels fluctuate, but do not establish menopause on their own.
How Age-Matched AMH Results Could Help
The work addresses a practical gap for women in midlife: AMH is used as a marker of ovarian reserve, but conventional assays can struggle to measure concentrations near the bottom of their range. That is relevant as levels decline, including during the period the report describes as a near-depletion phase around ages 44–49. An age-matched reference may give clinicians more context for interpreting a result than a single value without age-specific comparison.
If validated and used alongside other clinical information, the reference framework could help identify women who may benefit from earlier fertility discussions and provide another measure to consider when assessing perimenopausal symptoms. The symptom association does not show that low AMH causes symptoms, nor does the report establish that AMH-guided care improves outcomes. The findings about hormone replacement therapy are a possible clinical application, not evidence that a particular treatment is appropriate for an individual. Decisions about fertility and symptom management require discussion with a qualified clinician.
As an affiliate, we earn on qualifying purchases.
Why Midlife AMH Is Hard to Interpret
AMH is produced by cells in ovarian follicles and is used in clinical practice as an indicator of ovarian reserve. The report says many existing reference ranges are based on women of reproductive age, leaving fewer precise age-specific comparisons for women over 35, especially those approaching menopause. It also notes that standard assays may not be sensitive enough to distinguish very low concentrations reliably.
The study’s contribution is therefore a measurement and interpretation framework, rather than a new treatment or a replacement for existing menopause assessment. Its reference values were developed for Chinese women. They should not automatically be assumed to represent women from other populations, and a percentile describes a comparison with peers—not a complete measure of fertility or overall health.
“a woman’s exact age and locate her AMH value on this “coordinate chart””
— The study report, describing the age-specific reference framework
female ovarian reserve testing kit
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Limits of the New Reference Values
The supplied report does not give the cohort’s total size, detailed participant characteristics, or the full performance measures for the fertility and symptom associations. It also does not provide enough detail to assess how the hospital-based findings may apply to women outside that care setting. These details matter when judging how broadly the results can be applied.
The study reports associations, not proof that low AMH causes more severe symptoms or that use of the reference table changes fertility or menopause outcomes. It is also unclear from the material provided how well the ranges perform in populations beyond Chinese women, or how clinicians should combine the results with symptoms and other tests in specific cases. AMH alone should not be treated as a diagnosis of menopause.
As an affiliate, we earn on qualifying purchases.
Validation and Clinical Use Ahead
The immediate next step is further evaluation of the age-specific ranges and their clinical performance, including whether results can be reproduced in other populations and care settings. The supplied report does not announce a planned follow-up study, a change to clinical guidelines, or a timeline for routine adoption.
For now, the findings offer clinicians a potential reference tool to discuss alongside a patient’s age, symptoms, reproductive plans and other relevant test results. Anyone considering AMH testing or interpreting a result should consult a qualified health professional; the study does not support using the assay as a stand-alone basis for fertility or menopause decisions.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the study develop?
Researchers created age-specific AMH reference values for Chinese women aged 35–55, using an ultrasensitive assay designed to measure very low hormone concentrations.
Does a low AMH result diagnose menopause?
No. The study found only moderate ability to distinguish menopausal status using AMH alone. A low result may add information for a clinician, but it is not a stand-alone diagnosis.
What did the study report about fertility?
In the hospital-based group of women aged 35–40 who planned to conceive, those with AMH below the 10th percentile for their age had a higher risk of progressing to severely diminished ovarian reserve, defined as below 0.25 ng/mL. This finding does not determine whether an individual can conceive.
Were lower AMH levels linked to perimenopausal symptoms?
Yes. The researchers reported an association between lower AMH and a greater likelihood of more severe symptoms, particularly hot flashes and sweating. The report does not show that low AMH causes those symptoms.
Can the reference values be applied to everyone?
The reported reference table was developed for Chinese women. The supplied material does not establish that it applies equally to other populations, so broader use would require validation.
Source: rss
